Sign In
Buy EBS
$7.93
-0.280 (-3.41%)
At Close: Jun 03, 2026
Composite Rating For Emergent Biosolutions Rises To 99
10:27pm, Monday, 03'rd Aug 2020
Emergent Biosolutions saw its IBD SmartSelect Composite Rating jump to 99 Monday, up from 94 the day before. The upgrade means the stock currently tops 99% of all other stocks in terms of key performa
Emergent Biosolutions (NYSE:EBS) Sets New 52-Week High After Strong Earnings
01:50am, Sunday, 02'nd Aug 2020
Emergent Biosolutions Inc (NYSE:EBS) hit a new 52-week high during mid-day trading on Friday following a stronger than expected earnings report. The stock traded as high as $114.13 and last traded at
Emergent Biosolutions CEO: 'hyperfocused' on manufacturing COVID-19 vaccine candidates
07:26pm, Friday, 31'st Jul 2020
Emergent Biosolutions CEO Bob Kramer joins Yahoo Finance Akiko Fujita to discuss the company's earnings results and his outlook on developing a coronavirus vaccine.
Emergent (EBS) Beats Q2 Earnings Estimates, Ups '20 Guidance
07:08pm, Friday, 31'st Jul 2020
Emergent's (EBS) second-quarter earnings beat estimates on robust product sales. Concurrently, it increases its annual guidance.
Here's Why Emergent BioSolutions Stock Jumped Today
06:04pm, Friday, 31'st Jul 2020
The expert in bioterrorism and emerging infectious diseases had a great second quarter, with more to come.
Emergent BioSolutions Inc (EBS) Q2 2020 Earnings Call Transcript
01:01am, Friday, 31'st Jul 2020
EBS earnings call for the period ending June 30, 2020.
The Daily Biotech Pulse: Sanofi-GSK Land $2.1B Funding For Coronavirus Vaccine, D-Day For GW Pharma, FDA Nod For Roche
12:00am, Friday, 31'st Jul 2020
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 30)
Achieve Life Sciences Inc (NASDAQ: ACHV)
Annexon Inc (NASDAQ: ANNX) (IPOed July 24)
Atossa Therapeutics...
Emergent BioSolutions, Inc. (EBS) CEO Bob Kramer on Q2 2020 Results - Earnings Call Transcript
11:48pm, Thursday, 30'th Jul 2020
Emergent BioSolutions, Inc. (NYSE:EBS) Q2 2020 Earnings Conference Call July 30, 2020 17:00 ET Company Participants Bob Burrows - Vice President, Investor Relations Bob Kramer - President & Chief
* Establishes key collaborations with industry, U.S. government, and health care providers to help advance COVID-19 vaccine and therapeutic solutions * Current quarter and year-to-date performance
Drugmakers Race to Build Covid-19 Vaccine Supply Chains
12:41pm, Thursday, 30'th Jul 2020
Pharmaceutical companies that are racing to develop a vaccine for the coronavirus are already working behind the scenes to build the supply chains needed to deliver the drug to billions of people as r
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Annexon...
The Race To Erase COVID-19
01:21am, Wednesday, 29'th Jul 2020
As new COVID-19 cases both in the US and globally continue to rise, four leading biotech companies with competing technology offerings race to bring about a medical solution.
Is Emergent Biosolutions (EBS) Outperforming Other Medical Stocks This Year?
03:30pm, Tuesday, 28'th Jul 2020
Is (EBS) Outperforming Other Medical Stocks This Year?
Emergent Signs $174M Manufacturing Deal For AstraZeneca’s Covid-19 Candidate
11:19am, Tuesday, 28'th Jul 2020
Emergent BioSolutions Inc. (EBS) has signed a $174 million deal to provide contract development and manufacturing for AstraZeneca’s (AZN) COVID-19 vaccine candidate, AZD1222.As part of the agreement
Biotech Bonanza - Second Half Outlook
08:24am, Tuesday, 28'th Jul 2020
Biotech is one of the rare industries whose prospects have improved as the year has progressed. A low interest rate environment, a less hostile regulatory environment, and strong investor interest cre
